OBIO logo

OBIO
Orchestra BioMed Holdings Inc

521
Mkt Cap
$222.38M
Volume
25.00
52W High
$5.42
52W Low
$2.20
PE Ratio
-3.10
OBIO Fundamentals
Price
$3.99
Prev Close
$3.80
Open
$3.85
50D MA
$4.34
Beta
1.69
Avg. Volume
245,337.82
EPS (Annual)
-$1.11
P/B
4.25
Rev/Employee
$389,325.58
$133.88
Loading...
Loading...
News
all
press releases
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23h ago
News Placeholder
More News
News Placeholder
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Growth in Short Interest
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat·13d ago
News Placeholder
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports...
MarketBeat·18d ago
News Placeholder
Orchestra BioMed (OBIO) to Release Earnings on Wednesday
Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-1-orchestra-biomed-holdings-inc-stock...
MarketBeat·1mo ago
News Placeholder
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold reco...
MarketBeat·1mo ago
News Placeholder
HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - HC Wainwright boosted their Q1 2026 earnings per share estimates for Orchestra BioMed in a report released on Monday, March 16th. HC...
MarketBeat·1mo ago
News Placeholder
Orchestra BioMed (NASDAQ:OBIO) Insider Purchases 10,000 Shares
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David Hochman acquired 10,000 shares of Orchestra BioMed stock in a transaction that occurred on Friday, March 13th. The stock...
MarketBeat·2mo ago
News Placeholder
Orchestra BioMed (NASDAQ:OBIO) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of Orchestra BioMed from a "strong sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Orchestra BioMed (NASDAQ:OBIO) Receives "Buy" Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday...
MarketBeat·2mo ago
News Placeholder
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +168.87% and +3,813.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
<
1
2
...
>

Latest OBIO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.